Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.

Hammond JL, Parikh UM, Koontz DL, Schlueter-Wirtz S, Chu CK, Bazmi HZ, Schinazi RF, Mellors JW.

Antimicrob Agents Chemother. 2005 Sep;49(9):3930-2.

2.
3.

Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.

Hammond JL, Koontz DL, Bazmi HZ, Beadle JR, Hostetler SE, Kini GD, Aldern KA, Richman DD, Hostetler KY, Mellors JW.

Antimicrob Agents Chemother. 2001 Jun;45(6):1621-8.

5.

Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate.

Tramontano E, Piras G, Mellors JW, Putzolu M, Bazmi HZ, La Colla P.

Biochem Pharmacol. 1998 Dec 15;56(12):1583-9.

PMID:
9973178
6.

Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

Mellors JW, Bazmi HZ, Schinazi RF, Roy BM, Hsiou Y, Arnold E, Weir J, Mayers DL.

Antimicrob Agents Chemother. 1995 May;39(5):1087-92.

7.

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, Mellors JW.

Antimicrob Agents Chemother. 1993 Apr;37(4):875-81.

8.

Supplemental Content

Loading ...
Support Center